Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug.
Rabiya S
RS
Tuma
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D011905:Genes, ras / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D020930:MAP Kinase Kinase Kinases / Q000378:metabolism; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000378:metabolism*; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology*; D013997:Time Factors; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D011518:Proto-Oncogene Proteins; D013449:Sulfonamides; D000077484:Vemurafenib; D017479:Receptors, Platelet-Derived Growth Factor; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D019908:Proto-Oncogene Proteins c-raf; D020930:MAP Kinase Kinase Kinases; C069937:MAP3K8 protein, human